Boussard & Gavaudan Investment Management LLP : Form 8.3 -

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
40
Boussard & Gavaudan Investment Management LLP : Form 8.3 - Inmarsat plc

FORM 8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code")

1.         KEY INFORMATION

(a)  Identity of the person whose positions/dealings are being disclosed: Boussard & Gavaudan Investment Management LLP Boussard & Gavaudan Asset Management LP acting on behalf of various funds
(b) Owner or controller of interests and short positions disclosed, if different from 1(a):   The naming of nominee or vehicle companies is insufficient  
(c) Name of offeror/offeree in relation to whose relevant securities this form relates:   Use a separate form for each offeror/offeree   Inmarsat Plc
(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:  
(e)  Date position held/dealing undertaken: 02 nd July 2018
(f) Has the discloser previously disclosed, or are they today disclosing, under the Code in respect of any other party to this offer? No

2.         POSITIONS OF THE PERSON MAKING THE DISCLOSURE

(a)        Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

Class of relevant security:   Convertible Bond ISIN : XS1486508887
    Interests Short positions
Number % Number %
(1)  Relevant securities owned and/or controlled: 8,400,000 1.292%    
(2)  Derivatives CFD (other than options):      
(3)  Options and agreements to purchase/sell:    
  TOTAL: 8,400,000 1.292%    
Class of relevant security:   EUR 0.0005 ordinary ISIN: GB00B09LSH68
    Interests Short positions
Number % Number %
(1)  Relevant securities owned and/or controlled:        
(2)  Derivatives CFD (other than options):   2,653,755 0.575% 1,747,265 0.379 %
(3)  Options and agreements to purchase/sell:    
  TOTAL: 2,653,755 0.575% 1,747,265 0.379%

All interests and all short positions should be disclosed.Details of any open derivative or option positions, or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

(b)        Rights to subscribe for new securities (including directors' and other executive options)

Class of relevant security in relation to which subscription right exists:  
Details, including nature of the rights concerned and relevant percentages:  

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

3.         DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

(a)        Purchases and sales

Class of relevant security Purchase/sale   Number of securities Price per unit
Convertible Bond Purchase 1,000,000 143.00

 (b)       Derivatives transactions (other than options)

Class of relevant security Product description e.g. CFD Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position Number of reference securities Price per unit GBP
EUR 0.0005 ordinary   CFD Increasing a short position 208,065 7.50

(c)        Options transactions in respect of existing securities

(i)         Writing, selling, purchasing or varying

Class of relevant security Product description e.g. call option Writing, purchasing, selling, varying etc. Number of securities to which option relates Exercise price per unit Type e.g. American, European etc. Expiry date Option money paid/ received per unit
               

(ii)        Exercising

Class of relevant security Product description e.g. call option Number of securities Exercise price per unit
         

(d)        Other dealings (including subscribing for new securities)

Class of relevant security Nature of dealing e.g. subscription, conversion Details Price per unit (if applicable)
         

The currency of all prices and other monetary amounts should be stated. Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

4.         OTHER INFORMATION

(a)        Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: If there are no such agreements, arrangements or understandings, state "none"
     

(b)        Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i)  the voting rights of any relevant securities under any option; or (ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: If there are no such agreements, arrangements or understandings, state "none"
     

(c)        Attachments

Is a Supplemental Form 8 (Open Positions) attached ? NO
Date of disclosure: 03rd July 2018
Contact name:   Deborah Gewinner
Telephone number:   +44 203 751 54 12

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk .  The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .

Attachment

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Triumph Financial Sets Stage for Q4 Earnings and Insights

Updated Category News Views 196

Triumph Financial Plans Fourth Quarter Earnings Release Triumph Financial, Inc. (Nasdaq: TFIN) recently announced its anticipation for the release of fourth quarter financial results. This event is scheduled to take place after the market closes on an upcoming Wednesday. Along with the financial report, the company will provide management commentary for stakeholders and...

Continue Reading
Monitoring ABA Therapy Progress: A Parent's Guide

Updated Category News Views 6

The Nuts and Bolts of Progress Monitoring You've got a situation in Leominster where parents are trying to make sense of ABA therapy's impact on their kids. Rob Shapiro, a big name in the ABA world, breaks it all down in a HelloNation article. We're talking about precise data collection being the backbone of measuring progress in ABA therapy. This ain't no place for...

Continue Reading
Understanding Dowlais Group's Recent Market Activities

Updated Category News Views 185

Public Disclosure Regarding Dowlais Group's Trading Activity FORM 8.5 (EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code 1. KEY INFORMATION (a) Name of exempt principal trader: Investec Bank plc (b) Name of offeror/offeree in relation to whose r

Continue Reading
OFS Credit Company Reports Impressive Q4 Financials for 2024

Updated Category News Views 98

OFS Credit Company Delivers Strong Q4 2024 Financial Results OFS Credit Company, Inc. (NASDAQ: OCCI), a notable investment firm focusing on collateralized loan obligation (CLO) equity and debt securities, has announced its financial performance for the fiscal quarter ending October 31, 2024. This report outlines the company’s significant financial growth and strategic...

Continue Reading
Breakthrough Data on HBI-8000 and Nivolumab for Melanoma

Updated Category News Views 89

HBI-8000 and Nivolumab: A New Era in Melanoma Treatment Recent findings highlight the potential of HBI-8000 in combination with nivolumab, suggesting a transformative approach in the treatment of advanced melanoma. This promising combination will be discussed in detail at an upcoming prestigious annual meeting focused on advancements in immunotherapy. Innovative Solutions...

Continue Reading